Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenon (XENE – Research Report) and Kalaris Therapeutics (KLRS – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xenon (XENE)
In a report released today, Andrew Tsai from Jefferies assigned a Buy rating to Xenon, with a price target of $100.00. The company’s shares closed last Monday at $62.76.
According to TipRanks.com, Tsai is a 5-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $65.07, which is a 7.4% upside from current levels. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
See the top stocks recommended by analysts >>
Kalaris Therapeutics (KLRS)
William Blair analyst Lachlan Hanbury Brown assigned a Buy rating to Kalaris Therapeutics today and set a price target of $9.82. The company’s shares closed last Monday at $10.08, close to its 52-week low of $7.96.
According to TipRanks.com, Brown is a 4-star analyst with an average return of
Kalaris Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.96.
